India's SII could resume Covishield shot production as COVID cases rise

 

The Serum Institute of India (SII) could resume production of the Covishield COVID-19 vaccine, a company spokesperson said on Wednesday, as infections rise in the country.

The world's biggest vaccine maker already has a stock of 6 million doses of Covovax, a version of a Novavax vaccine, the spokesperson added. Covishield is a version of an AstraZeneca shot.

https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/India-s-SII-could-resume-Covishield-shot-production-as-COVID-cases-rise-43475451/